{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-292953","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2022-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.553811+00:00","generated_at":"2026-06-21T12:50:21.684277+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ikena Oncology nominates IK-595 as first RAS pathway candidate; IND targeted H2 2023","bullets":["IK-595: MEK-RAF complex inhibitor traps MEK & RAF in inactive complex, aims to avoid resistance.","Discontinuing IK-007 (EP4 antagonist) internal development; exploring strategic alternatives.","Cash runway extended into 2025; does not include potential IK-175 opt-in fees from BMS.","IK-930 TEAD inhibitor monotherapy initial clinical data expected H2 2023; osimertinib combo starts H1 2023.","Preclinical differentiation data for IK-595 planned for H1 2023; RAS pathway implicated in >500K US cancer cases/yr."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-292953","json":"https://secwatch.observer/filing/0001193125-22-292953.json","markdown":"https://secwatch.observer/filing/0001193125-22-292953.md","text":"https://secwatch.observer/filing/0001193125-22-292953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522292953/0001193125-22-292953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312522292953/d420821d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:50:21.684277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}